About
Corporate Overview
Founder
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
CEO Updates
Articles & Discussions
Video News
Hiring
Videos
News
CEO Updates
Patient Testimonials
Publications
Technology Overview
Manufacturing
Intellectual Property
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Blog
Investor
Investor Presentation
Overview
Public Filings
AGM Materials
Investor enquiry
MENU ≡
About
Corporate Overview
Founder
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
CEO Updates
Articles & Discussions
Video News
Hiring
Videos
News
CEO Updates
Patient Testimonials
Publications
Technology Overview
Manufacturing
Intellectual Property
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Blog
Investor
Investor Presentation
Overview
Public Filings
AGM Materials
Investor enquiry
News & Media
all
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Aug 01
/ 2024
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Jun 11
/ 2024
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Jun 03
/ 2024
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Mar 07
/ 2024
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Feb 06
/ 2024
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
